CRINECERFONT | NEUROCRINE | ||
25MG,50MG,100MG | |||
No | No | ||
2041-Jun-09 | 2029-Dec-13 | ||
None | None | ||
None | No | ||
CRENESSITY is a corticotropin-releasing factor type 1 receptor antagonist indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH). |
0 | 0 | 0 |
Total Other Developers | None |
---|
Drugs with Suitability | No |
---|
25MG | ** | ** | - | - | - |
50MG | ** | ** | - | - | - |
100MG | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
No | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com